Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Snag a refurbished iPad Air on sale for $150
Mark Zuckerberg ACCEPTS Elon Musk’s challenge to a cage fight
Fortnite Chapter 4 Season 5 Leaks: Planes, Ballers, and Traps Returning
A lifetime subscription to Babbel is on sale for 54% off
Explainer-What to expect when Hurricane Idalia hits Florida on Wednesday
Risk of Summer Blackouts Stretches Into US Southeast for First Time
FIFA 23 94+ FUTTIES Player Pick SBC: How to Complete
Is Kai Cenat in love? Streamer freaked out when crush shared his Twitch clip on Instagram, fans called him ‘cutie’